{
    "pmcid": "PMC11730665",
    "title": "Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis",
    "study_parameters": {
        "summary": {
            "content": "This study aimed to compare the efficacy and safety of sitagliptin versus gliclazide, both combined with metformin, in treatment-naive patients with type 2 diabetes mellitus and glucotoxicity. Conducted as a single-center, randomized, controlled noninferiority trial, it involved 129 participants who received either sitagliptin or gliclazide for 4 weeks, followed by metformin monotherapy for 8 weeks. The results demonstrated that sitagliptin was noninferior to gliclazide in reducing glycated hemoglobin, with sitagliptin achieving faster glycemic targets and greater weight reductions, while genetic polymorphisms significantly influenced drug efficacy.",
            "citations": [
                "After 12 weeks, mean glycated hemoglobin reductions were 4.03% in the sitagliptin group and 4.13% in the gliclazide group, with a mean difference of \u22120.097 (95% confidence interval, \u22120.648 to 0.453), confirming noninferiority.",
                "The sitagliptin group achieved faster glycemic targets, greater FPG and body weight reductions, and higher rates of FPG < 6.1 mmol/L (26.2% vs 5.7%; P = .012).",
                "Genetic analysis showed specific single-nucleotide polymorphisms affected drug efficacy: dipeptidyl peptidase-4 rs2909451 TT and rs4664443 GG genotypes showed lower efficacy with sitagliptin, while GLP1R rs3765467 AG and KCNJ11 rs2285676 CC genotypes responded better to sitagliptin."
            ]
        },
        "study_type": {
            "content": "Clinical trial, GWAS, prospective",
            "citations": [
                "In this single-center, randomized, controlled noninferiority trial, 129 treatment-naive patients with T2DM with glucotoxicity (fasting plasma glucose [FPG] \u2265 200 mg/dL and glycated hemoglobin \u2265 9.0%) were randomized to receive sitagliptin plus metformin (n = 66) or gliclazide plus metformin (n = 63) for 12 weeks.",
                "Whole genome analysis techniques were employed to investigate the impact of genetic polymorphisms on drug efficacy and safety.",
                "Whole genome sequencing was performed on the extracted DNA samples using the Illumina HiSeq X Ten platform (Illumina, San Diego, CA), achieving a coverage depth of over 1000-fold per sample to ensure high-quality genomic data."
            ]
        },
        "participant_info": {
            "content": "The study included 129 treatment-naive patients with type 2 diabetes mellitus (T2DM) who were recruited from Nanfang Hospital of Southern Medical University. Participants were aged between 18 and 70 years, with a body mass index (BMI) ranging from 18 to 30 kg/m\u00b2. The study group consisted of 61 participants, while the control group included 53 participants. There were no statistically significant differences between the groups in terms of gender distribution, age, height, weight, BMI, fasting plasma glucose (FPG), or glycated hemoglobin (HbA1c) at baseline, indicating homogeneity across the cohorts. The study did not specify the ethnicity of the participants, and all had normal hepatic and renal function, with no prior use of hypoglycemic medications or severe diabetes-related complications.",
            "citations": [
                "The inclusion criteria are given as follows: demonstrably understand the study objectives with voluntary participation, documented by signed informed consent; newly diagnosed, treatment-naive individuals with T2DM; the age range is between 18 and 70 years, with a body mass index (BMI) ranging from 18 to 30 kg/m\u00b2; normal hepatic and renal function, defined as alanine aminotransferase and aspartate aminotransferase levels not exceeding 2.5\u00d7 the upper limit of normal, serum creatinine within normal limits, and urine ketone bodies not exceeding (1+); fasting plasma glucose (FPG) levels \u2265 200 mg/dL (11.1 mmol/L) and glycated hemoglobin (HbA1c) \u2265 9.0%; and capability to adhere to the prescribed antidiabetic regimen, follow dietary guidelines, and self-monitor fasting and postprandial blood glucose levels.",
                "This study initially screened 156 individuals, of whom 129 were randomized. Within the randomized cohort, 66 participants were allocated to the intervention group, and 61 were included in the final analysis. For the control group, 63 were allocated, and 53 were included in the final analysis (Fig. [1](#F1)1). There were no statistically significant differences between the groups in terms of gender, age, height, weight, BMI, FPG, or HbA1c at baseline, indicating homogeneity across the cohorts (*P*P > .05; Table [1](#T1)1).",
                "Participants were recruited from Nanfang Hospital of Southern Medical University between September 1, 2023, and March 1, 2024."
            ]
        },
        "study_design": {
            "content": "The study was a single-center, prospective, randomized, controlled, noninferiority trial conducted at Nanfang Hospital of Southern Medical University. It included 129 treatment-naive patients with type 2 diabetes mellitus (T2DM) and glucotoxicity, characterized by fasting plasma glucose levels of at least 200 mg/dL and glycated hemoglobin levels of at least 9.0%. Participants were randomized to receive either sitagliptin plus metformin (66 patients) or gliclazide plus metformin (63 patients) for a total of 12 weeks. The initial 4 weeks involved combination therapy with sitagliptin or gliclazide, followed by 8 weeks of metformin monotherapy. The study aimed to evaluate changes in glycemic control, body weight, and \u03b2-cell function, with genetic polymorphism analysis conducted to assess the impact of specific genotypes on drug efficacy.",
            "citations": [
                "In this single-center, randomized, controlled noninferiority trial, 129 treatment-naive patients with T2DM with glucotoxicity (fasting plasma glucose [FPG] \u2265 200 mg/dL and glycated hemoglobin \u2265 9.0%) were randomized to receive sitagliptin plus metformin (n = 66) or gliclazide plus metformin (n = 63) for 12 weeks.",
                "Sitagliptin and gliclazide were given for the first 4 weeks, followed by metformin monotherapy for 8 weeks.",
                "Efficacy end points included changes in glycemic control, body weight, and \u03b2-cell function at baseline, 4 weeks, and 12 weeks."
            ]
        },
        "study_results": {
            "content": "The study found that sitagliptin combined with metformin is noninferior to gliclazide combined with metformin in treatment-naive patients with type 2 diabetes mellitus (T2DM) with glucotoxicity. After 12 weeks, both groups showed significant reductions in glycated hemoglobin (HbA1c) levels, with a mean difference of \u22120.097% (95% CI, \u22120.648 to 0.453), confirming noninferiority. The sitagliptin group achieved faster glycemic targets, greater fasting plasma glucose (FPG) and body weight reductions, and higher rates of FPG < 6.1 mmol/L (26.2% vs 5.7%; P = .012). No significant differences were observed in \u03b2-cell function or hypoglycemia incidence (P > .05). Genetic polymorphisms significantly affected drug efficacy, with specific genotypes showing varied responses to sitagliptin, highlighting the importance of personalized medicine.",
            "citations": [
                "After 12 weeks, mean glycated hemoglobin reductions were 4.03% in the sitagliptin group and 4.13% in the gliclazide group, with a mean difference of \u22120.097 (95% confidence interval, \u22120.648 to 0.453), confirming noninferiority.",
                "The sitagliptin group achieved faster glycemic targets, greater FPG and body weight reductions, and higher rates of FPG < 6.1 mmol/L (26.2% vs 5.7%; P = .012).",
                "Genetic analysis showed specific single-nucleotide polymorphisms affected drug efficacy: dipeptidyl peptidase-4 rs2909451 TT and rs4664443 GG genotypes showed lower efficacy with sitagliptin, while GLP1R rs3765467 AG and KCNJ11 rs2285676 CC genotypes responded better to sitagliptin."
            ]
        },
        "allele_frequency": {
            "content": "The article does not provide specific information about the allele frequencies of the genetic variants studied in the population. It focuses on the impact of genetic polymorphisms on the efficacy of sitagliptin and gliclazide, highlighting specific genotypes that influence drug response, but it does not detail the allele frequencies within the study cohorts.",
            "citations": [
                "Genetic analysis showed specific single-nucleotide polymorphisms affected drug efficacy: dipeptidyl peptidase-4 rs2909451 TT and rs4664443 GG genotypes showed lower efficacy with sitagliptin, while GLP1R rs3765467 AG and KCNJ11 rs2285676 CC genotypes responded better to sitagliptin.",
                "Genotypes at target loci, including DPP-4, GLP1R, KCNQ1, KCNJ11, CDKAL1, CYP2C9, and CYP2C19, were ascertained for each participant.",
                "The analysis revealed significant effects of DPP-4 gene polymorphisms on the efficacy of sitagliptin."
            ]
        },
        "additional_resource_links": [
            "The study provides the following additional resources or links related to its design and execution:",
            "1. **DOI Link to the Article:** [10.1097/MD.0000000000041061](https://doi.org/10.1097/MD.0000000000041061)",
            "2. **PubMed Central (PMC) Article Link:** [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730665/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730665/)",
            "3. **PDF of the Article:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC11730665/pdf/medi-104-e41061.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC11730665/pdf/medi-104-e41061.pdf)",
            "These resources provide access to the full text of the study, including detailed information on the study's design and execution."
        ]
    },
    "annotations": {
        "relationships": [
            {
                "gene": "DPP-4",
                "polymorphism": "rs2909451 TT",
                "relationship_effect": "Patients with the TT genotype had lower efficacy with sitagliptin (median HbA1c improvement 0.57) compared to gliclazide (1.11).",
                "p_value": "<.001",
                "citations": [
                    "The analysis revealed significant effects of DPP-4 gene polymorphisms on the efficacy of sitagliptin. Patients with the rs2909451 TT genotype in the study group (treated with sitagliptin) exhibited a median HbA1c improvement of 0.57 (interquartile range [IQR], 0.18\u20130.85), whereas the control group (treated with gliclazide) showed a median improvement of 1.11 (IQR, 0.86\u20131.35; *P*P < .001).",
                    "## Table 6. Comparison of the median (IQR) glycated hemoglobin improvement and P values between the study group and control group across different genotypes.",
                    "The efficacy of sitagliptin, a DPP-4 inhibitor, can be influenced by genetic variations in the DPP-4 gene. Specifically, individuals with specific genotypes, such as the TT genotype of rs2909451 and GG genotype of rs4664443, may experience lower efficacy of sitagliptin.^[52]^[[52](#R52)52]"
                ]
            },
            {
                "gene": "DPP-4",
                "polymorphism": "rs4664443 GG",
                "relationship_effect": "Patients with the GG genotype had lower efficacy with sitagliptin (median HbA1c improvement 0.69) compared to gliclazide (1.25).",
                "p_value": "<.001",
                "citations": [
                    "Similarly, for the rs4664443 GG genotype, the median HbA1c improvement in the study group was 0.69 (IQR, 0.48\u20130.91) compared with 1.25 (IQR, 1.00\u20131.46) in the control group (*P*P < .001), indicating lower efficacy of sitagliptin.",
                    "Genetic polymorphisms, such as DPP-4 rs2909451 TT and rs4664443 GG, significantly influenced the efficacy of sitagliptin, highlighting the importance of personalized medicine."
                ]
            },
            {
                "gene": "GLP1R",
                "polymorphism": "rs6923761 AA",
                "relationship_effect": "Patients with the AA genotype had reduced glycemic response to sitagliptin (median HbA1c improvement 0.90) compared to gliclazide (1.41).",
                "p_value": ".010",
                "citations": [
                    "Regarding GLP1R gene polymorphisms, patients with the rs6923761 AA homozygous genotype in the study group had a median HbA1c improvement of 0.90 (IQR, 0.61\u20131.01), while the control group showed 1.41 (IQR, 1.12\u20131.45; *P*P = .010), suggesting reduced glycemic response to sitagliptin.",
                    "## Table 6. Comparison of the median (IQR) glycated hemoglobin improvement and P values between the study group and control group across different genotypes.",
                    "Genetic polymorphisms significantly affect drug efficacy, highlighting the importance of personalized medicine."
                ]
            },
            {
                "gene": "GLP1R",
                "polymorphism": "rs3765467 AG",
                "relationship_effect": "Patients with the AG genotype responded better to sitagliptin (median HbA1c improvement 1.42) than gliclazide (1.08).",
                "p_value": ".023",
                "citations": [
                    "Conversely, patients with the rs3765467 AG genotype in the study group demonstrated a median HbA1c improvement of 1.42 (IQR, 1.22\u20131.68) compared with 1.08 (IQR, 0.97\u20131.15) in the control group (*P*P = .023), indicating favorable responses to both treatments.",
                    "Regarding GLP1R gene polymorphisms, patients with the rs6923761 AA homozygous genotype in the study group had a median HbA1c improvement of 0.90 (IQR, 0.61\u20131.01), while the control group showed 1.41 (IQR, 1.12\u20131.45; *P*P = .010), suggesting reduced glycemic response to sitagliptin. Conversely, patients with the rs3765467 AG genotype in the study group demonstrated a median HbA1c improvement of 1.42 (IQR, 1.22\u20131.68) compared with 1.08 (IQR, 0.97\u20131.15) in the control group (*P*P = .023), indicating favorable responses to both treatments."
                ]
            },
            {
                "gene": "KCNQ1",
                "polymorphism": "rs163184 GG",
                "relationship_effect": "Patients with the GG allele had lower responsiveness to sitagliptin (median HbA1c improvement 0.81) and better response to gliclazide (1.16).",
                "p_value": "<.001",
                "citations": [
                    "KCNQ1 gene polymorphisms also significantly affected treatment outcomes. Patients with the rs163184 GG allele in the study group had a median HbA1c improvement of 0.81 (IQR, 0.62\u20130.92) compared with 1.16 (IQR, 0.91\u20131.32) in the control group (*P*P < .001), suggesting lower responsiveness to sitagliptin and better response to gliclazide.",
                    "## Table 6. Comparison of the median (IQR) glycated hemoglobin improvement and P values between the study group and control group across different genotypes.",
                    "The Manhattan plot shows the overall distribution of single-nucleotide polymorphism associations across the genome, highlighting key loci such as rs2909451, rs4664443, rs163184, and rs2285676, which are strongly associated with differential HbA1c improvements and underscore the genetic influence on therapeutic response (Fig. [6](#F6)6)."
                ]
            },
            {
                "gene": "KCNJ11",
                "polymorphism": "rs2285676 CC",
                "relationship_effect": "Patients with the CC genotype responded better to sitagliptin (median HbA1c improvement 1.02) than gliclazide (1.31).",
                "p_value": "<.001",
                "citations": [
                    "For KCNJ11 gene polymorphisms, patients with the rs2285676 CC genotype in the study group had a median HbA1c improvement of 1.02 (IQR, 0.90\u20131.22), while the control group showed 1.31 (IQR, 1.08\u20131.42; *P*P < .001), indicating more substantial insulin secretion capability with sitagliptin.",
                    "Comparison of the median (IQR) glycated hemoglobin improvement and P values between the study group and control group across different genotypes.",
                    "| Genotype | Study group, median (IQR) | Control group, median (IQR) | P value |"
                ]
            },
            {
                "gene": "CDKAL1",
                "polymorphism": "rs7754840 CG",
                "relationship_effect": "Patients with the CG genotype had greater HbA1c reduction with sitagliptin (1.44) than gliclazide (1.09).",
                "p_value": ".053",
                "citations": [
                    "CDKAL1 gene variants, specifically rs7754840 CG and rs756992 AG, were associated with more significant HbA1c reductions in the study group.",
                    "Patients with the rs7754840 CG genotype showed a median improvement of 1.44 (IQR, 1.38\u20131.72) in the study group compared with 1.09 (IQR, 0.79\u20131.17) in the control group (*P*P = .053).",
                    "## Table 6: Comparison of the median (IQR) glycated hemoglobin improvement and P values between the study group and control group across different genotypes."
                ]
            },
            {
                "gene": "CDKAL1",
                "polymorphism": "rs756992 AG",
                "relationship_effect": "Patients with the AG genotype had greater HbA1c reduction with sitagliptin (1.43) than gliclazide (1.10).",
                "p_value": ".081",
                "citations": [
                    "CDKAL1 gene variants, specifically rs7754840 CG and rs756992 AG, were associated with more significant HbA1c reductions in the study group.",
                    "Similarly, patients with the rs756992 AG genotype exhibited a median improvement of 1.43 (IQR, 1.28\u20131.52) in the study group compared with 1.10 (IQR, 0.87\u20131.18) in the control group (*P*P = .081).",
                    "Comparison of the median (IQR) glycated hemoglobin improvement and P values between the study group and control group across different genotypes."
                ]
            },
            {
                "gene": "CYP2C9",
                "polymorphism": "rs1799853 TT",
                "relationship_effect": "Patients with the TT genotype had lower efficacy with sitagliptin (0.70) compared to gliclazide (1.07), suggesting slower metabolism of gliclazide impacts efficacy.",
                "p_value": "<.001",
                "citations": [
                    "CYP2C9 gene polymorphisms also significantly influenced treatment efficacy. Patients with the rs1799853 TT genotype in the study group had a median HbA1c improvement of 0.70 (IQR, 0.69\u20130.72), while the control group showed 1.07 (IQR, 0.82\u20131.42; *P*P < .001).",
                    "These findings suggest that rs1799853 and rs1057910 variants lead to slower metabolism of gliclazide, thereby impacting drug efficacy and adverse event rates (Table [6](#T6)6; Fig. [5](#F5)5).",
                    "Comparison of the median (IQR) glycated hemoglobin improvement and P values between the study group and control group across different genotypes."
                ]
            },
            {
                "gene": "CYP2C9",
                "polymorphism": "rs1057910 GG",
                "relationship_effect": "Patients with the GG genotype had similar efficacy with sitagliptin (0.93) and gliclazide (1.20); slower metabolism of gliclazide may impact efficacy and adverse events.",
                "p_value": ".464",
                "citations": [
                    "For the rs1057910 GG genotype, the study group exhibited a median improvement of 0.93 (IQR, 0.66\u20131.21) compared with 1.20 (IQR, 0.89\u20131.30) in the control group (*P*P = .464).",
                    "These findings suggest that rs1799853 and rs1057910 variants lead to slower metabolism of gliclazide, thereby impacting drug efficacy and adverse event rates (Table [6](#T6)6; Fig. [5](#F5)5).",
                    "## Table 6. Comparison of the median (IQR) glycated hemoglobin improvement and P values between the study group and control group across different genotypes."
                ]
            }
        ]
    }
}